// App-Quantinova.ai

THU0203 : REAL WORLD EFFECTIVENESS OF BARICITINIB IN THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)

Researchers

Presenter

  • B. Gilbert

Principal Investigators

  • K. Lauper

  • D. Courvoisier

  • C. Perrier

  • R. Muller

  • A. Finckh

Medical Centers

  • Hôpitaux Universitaires de Genève (HUG), Division of Rheumatology, Genève, Switzerland

  • The University of Manchester, Centre for Epidemiology Versus Arthritis, M13 9PT, United Kingdom

  • Eli Lilly, (Suisse) SA, Vernier, Switzerland

  • Kantonsspital Aarau AG, Klinik für Rheumatologie, Aarau, Switzerland

Locations

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Baricitinib

  • Rituximab

  • BARI

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved